388 related articles for article (PubMed ID: 27742220)
1. Characterization of the protective immune response to Yersinia pseudotuberculosis infection in mice vaccinated with an LcrV-secreting strain of Lactococcus lactis.
Daniel C; Titecat M; Poiret S; Cayet D; Boutillier D; Simonet M; Sirard JC; Lemaître N; Sebbane F
Vaccine; 2016 Nov; 34(47):5762-5767. PubMed ID: 27742220
[TBL] [Abstract][Full Text] [Related]
2. Protection against Yersinia pseudotuberculosis infection conferred by a Lactococcus lactis mucosal delivery vector secreting LcrV.
Daniel C; Sebbane F; Poiret S; Goudercourt D; Dewulf J; Mullet C; Simonet M; Pot B
Vaccine; 2009 Feb; 27(8):1141-4. PubMed ID: 19135495
[TBL] [Abstract][Full Text] [Related]
3. Polymorphism in the
Daniel C; Dewitte A; Poiret S; Marceau M; Simonet M; Marceau L; Descombes G; Boutillier D; Bennaceur N; Bontemps-Gallo S; Lemaître N; Sebbane F
Front Immunol; 2019; 10():1830. PubMed ID: 31428104
[TBL] [Abstract][Full Text] [Related]
4. A Recombinant Attenuated
Singh AK; Curtiss R; Sun W
Infect Immun; 2019 Oct; 87(10):. PubMed ID: 31331960
[TBL] [Abstract][Full Text] [Related]
5. Vaccine Potential of a Recombinant Bivalent Fusion Protein LcrV-HSP70 Against Plague and Yersiniosis.
Gupta A; Narayan B; Kumar S; Verma SK
Front Immunol; 2020; 11():988. PubMed ID: 32595634
[TBL] [Abstract][Full Text] [Related]
6. LcrV delivered via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances immunogenicity against pneumonic plague.
Sun W; Sanapala S; Henderson JC; Sam S; Olinzock J; Trent MS; Curtiss R
Infect Immun; 2014 Oct; 82(10):4390-404. PubMed ID: 25114109
[TBL] [Abstract][Full Text] [Related]
7. CD8(+) T cells specific to a single Yersinia pseudotuberculosis epitope restrict bacterial replication in the liver but fail to provide sterilizing immunity.
Shen H; Gonzalez-Juarbe N; Blanchette K; Crimmins G; Bergman MA; Isberg RR; Orihuela CJ; Dube PH
Infect Genet Evol; 2016 Sep; 43():289-96. PubMed ID: 27268148
[TBL] [Abstract][Full Text] [Related]
8. Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge.
Wang S; Goguen JD; Li F; Lu S
Vaccine; 2011 Sep; 29(39):6802-9. PubMed ID: 21199697
[TBL] [Abstract][Full Text] [Related]
9. HSP70 domain II of Mycobacterium tuberculosis modulates immune response and protective potential of F1 and LcrV antigens of Yersinia pestis in a mouse model.
Batra L; Verma SK; Nagar DP; Saxena N; Pathak P; Pant SC; Tuteja U
PLoS Negl Trop Dis; 2014 Dec; 8(12):e3322. PubMed ID: 25474358
[TBL] [Abstract][Full Text] [Related]
10. Mucosal co-immunization of mice with recombinant lactococci secreting VapA antigen and leptin elicits a protective immune response against Rhodococcus equi infection.
Cauchard S; Bermúdez-Humarán LG; Blugeon S; Laugier C; Langella P; Cauchard J
Vaccine; 2011 Dec; 30(1):95-102. PubMed ID: 22019740
[TBL] [Abstract][Full Text] [Related]
11. A Combined YopB and LcrV Subunit Vaccine Elicits Protective Immunity against
Heine SJ; Franco-Mahecha OL; Sears KT; Drachenberg CB; van Roosmalen ML; Leenhouts K; Picking WL; Pasetti MF
J Immunol; 2019 Apr; 202(7):2005-2016. PubMed ID: 30787109
[No Abstract] [Full Text] [Related]
12. YopE specific CD8+ T cells provide protection against systemic and mucosal Yersinia pseudotuberculosis infection.
González-Juarbe N; Shen H; Bergman MA; Orihuela CJ; Dube PH
PLoS One; 2017; 12(2):e0172314. PubMed ID: 28207901
[TBL] [Abstract][Full Text] [Related]
13. A protective epitope in type III effector YopE is a major CD8 T cell antigen during primary infection with Yersinia pseudotuberculosis.
Zhang Y; Mena P; Romanov G; Lin JS; Smiley ST; Bliska JB
Infect Immun; 2012 Jan; 80(1):206-14. PubMed ID: 22064714
[TBL] [Abstract][Full Text] [Related]
14. Oral vaccination with LcrV from Yersinia pestis KIM delivered by live attenuated Salmonella enterica serovar Typhimurium elicits a protective immune response against challenge with Yersinia pseudotuberculosis and Yersinia enterocolitica.
Branger CG; Torres-Escobar A; Sun W; Perry R; Fetherston J; Roland KL; Curtiss R
Vaccine; 2009 Aug; 27(39):5363-70. PubMed ID: 19596407
[TBL] [Abstract][Full Text] [Related]
15. LcrV synthesis is altered by DNA adenine methylase overproduction in Yersinia pseudotuberculosis and is required to confer immunity in vaccinated hosts.
Badie G; Heithoff DM; Mahan MJ
Infect Immun; 2004 Nov; 72(11):6707-10. PubMed ID: 15501808
[TBL] [Abstract][Full Text] [Related]
16. Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.
Arnaboldi PM; Sambir M; D'Arco C; Peters LA; Seegers JF; Mayer L; McCormick AA; Dattwyler RJ
Vaccine; 2016 Nov; 34(47):5768-5776. PubMed ID: 27745954
[TBL] [Abstract][Full Text] [Related]
17. YopJ-promoted cytotoxicity and systemic colonization are associated with high levels of murine interleukin-18, gamma interferon, and neutrophils in a live vaccine model of Yersinia pseudotuberculosis infection.
Zhang Y; Bliska JB
Infect Immun; 2010 May; 78(5):2329-41. PubMed ID: 20231414
[TBL] [Abstract][Full Text] [Related]
18. Prevention and treatment of colitis with Lactococcus lactis secreting the immunomodulatory Yersinia LcrV protein.
Foligne B; Dessein R; Marceau M; Poiret S; Chamaillard M; Pot B; Simonet M; Daniel C
Gastroenterology; 2007 Sep; 133(3):862-74. PubMed ID: 17678918
[TBL] [Abstract][Full Text] [Related]
19. CD8(+) T cells restrict Yersinia pseudotuberculosis infection: bypass of anti-phagocytosis by targeting antigen-presenting cells.
Bergman MA; Loomis WP; Mecsas J; Starnbach MN; Isberg RR
PLoS Pathog; 2009 Sep; 5(9):e1000573. PubMed ID: 19730693
[TBL] [Abstract][Full Text] [Related]
20. A recombinant bivalent fusion protein rVE confers active and passive protection against Yersinia enterocolitica infection in mice.
Singh AK; Kingston JJ; Murali HS; Batra HV
Vaccine; 2014 Mar; 32(11):1233-9. PubMed ID: 24486353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
